Regulus Therapeutics Inc. (RGLS) Sees Large Volume Increase
Regulus Therapeutics Inc. (NASDAQ:RGLS) saw strong trading volume on Monday . 1,186,142 shares traded hands during mid-day trading, an increase of 42% from the previous session’s volume of 838,206 shares.The stock last traded at $1.36 and had previously closed at $1.31.
A number of brokerages have commented on RGLS. ValuEngine downgraded shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th. BMO Capital Markets set a $1.00 price objective on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research report on Monday, June 12th. Wedbush restated an “ourperform” rating and set a $6.00 price objective on shares of Regulus Therapeutics in a research report on Tuesday, June 13th. Finally, Chardan Capital cut their price objective on shares of Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating for the company in a research report on Tuesday, June 13th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $3.63.
Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million.
In other Regulus Therapeutics news, CFO Daniel R. Chevallard purchased 54,945 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were purchased at an average cost of $0.91 per share, for a total transaction of $49,999.95. Following the completion of the transaction, the chief financial officer now owns 59,415 shares in the company, valued at $54,067.65. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William H. Rastetter purchased 274,725 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was acquired at an average price of $0.91 per share, for a total transaction of $249,999.75. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 549,450 shares of company stock worth $500,000. 4.80% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the business. Teachers Advisors LLC raised its position in Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after acquiring an additional 9,804 shares in the last quarter. Quantitative Investment Management LLC bought a new stake in Regulus Therapeutics in the second quarter worth about $103,000. Tudor Investment Corp ET AL raised its position in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 61,373 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Regulus Therapeutics in the second quarter worth about $139,000. Finally, LMR Partners LLP bought a new stake in Regulus Therapeutics in the second quarter worth about $164,000. Hedge funds and other institutional investors own 21.92% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.